Incentive device improves spacer technique but not clinical outcome in preschool children with asthma.
Incentive device improves spacer technique but not clinical outcome in preschool children with asthma.
复制标题
激励装置改善了间隔技术，但没有改善学龄前哮喘儿童的临床结果。
DOI：
10.1111/j.1440-1754.2011.02190.x
复制
发表时间：
2012
影响因子：
1.7
通讯作者：
Devadason,SunaleneG
中科院分区：
文献类型：
--
作者：
Schultz,Andre;Sly,PeterD;Zhang,Guicheng;Venter,Andre;LeSouef,PeterN;Devadason,SunaleneG
目的：探讨一种激励装置，Funhaler，对间隔技术和症状控制的幼儿哮喘和反复喘息，方法：随机对照试验，其中132 2 2-6岁的哮喘儿童定期吸入氟替卡松通过Aerochamber Plus，或Funhaler。研究地点是澳大利亚珀斯玛格丽特公主儿童医院的一个研究诊所。受试者随访一年。主要结果指标是哮喘症状。通过将沙丁胺醇从间隔器吸入过滤器来测量间隔器技术的熟练程度。每三个月测量一次生活质量。比较两组的融合器技术、症状和生活质量。结果：Funhaler组与Aerochamber组在无喘息、无咳嗽、无支气管扩张剂及生活质量方面无显著性差异（P= 0.90，0.87，0.74和0.11）。 Funhaler组的融合器技术更好（P= 0.05），特别是在4岁以下的受试者中（P= 0.002）。 过滤器上的药物剂量（5个100 mg剂量的平均值）范围为0至136 mg。结论：使用Funhaler激励装置不会改善临床结局，但会改善4岁以下儿童的间隔器技术。 在使用加压定量吸入器和间隔器的幼儿中，药物递送的变异性很大。
Aim:To investigate the influence of an incentive device, the Funhaler, on spacer technique and symptom control in young children with asthma and recurrent wheeze.Methods:Randomised controlled trial where 132 2–6 year old asthmatic children received regular inhaled fluticasone through Aerochamber Plus, or Funhaler. The setting was a research clinic at Princess Margaret Hospital for Children, Perth, Australia. Subjects were followed up for a year. The main outcome measure was asthma symptoms. Proficiency in spacer technique was measured as salbutamol inhaled from spacer onto filter. Quality of life was measured every three months. Groups were compared in terms of spacer technique, symptoms and quality of life. The relationship between spacer technique and clinical outcome was examined.Results:There was no difference between Funhaler and Aerochamber groups in wheeze free days, cough free days, bronchodilator free days or quality of life (P= 0.90, 0.87, 0.74 and 0.11 respectively). Spacer technique was better in the Funhaler group (P= 0.05), particularly in subjects younger than 4 years of age (P= 0.002). Drug dose on filter (as the mean of five 100 mg doses) ranged from zero to 136 mg.Conclusions:Use of Funhaler incentive device does not improve clinical outcome, but improves spacer technique in children younger than 4 years. Variability in drug delivery is large in young children using pressurised metered dose inhalers and spacers.
登录
查看更多内容
人副流感3型病毒特异多肽的细胞内合成
影响因子：
5.4
作者：
S. Wechsler;D. Lambert;M. Galinski;M. Pons
通讯作者：
M. Pons
有包膜病毒中肌动蛋白的存在
DOI：
--
发表时间：
1976
期刊：
影响因子：
--
作者：
E. Wang;B. A. Wolf;R. Lamb;P. Choppin;A. R. Goldberg
通讯作者：
A. R. Goldberg
人副流感病毒3病毒颗粒蛋白和基因组RNA的结构表征
影响因子：
5.4
作者：
D. Storey;K. Dimock;C. Kang
通讯作者：
C. Kang
淋巴细胞质膜脂质双层中细胞表面抗原的定向
影响因子：
64.8
作者：
F. Walsh;M. Crumpton
通讯作者：
M. Crumpton
3型副流感病毒蛋白亚单位疫苗：对羔羊和小鼠的免疫原性作用。
DOI：
10.1099/0022-1317-64-7-1557
发表时间：
1983
期刊：
The Journal of general virology
影响因子：
--
作者：
B. Morein;M. Sharp;B. Sundquist;K. Simons
通讯作者：
K. Simons